Showing posts with label EGFR-mutated lung cancer in first-line treatment. Show all posts
Showing posts with label EGFR-mutated lung cancer in first-line treatment. Show all posts
Thursday, March 24, 2016

Afatinib a better choice for EGFR-mutated lung cancer in first-line treatment

›
In continuation of my update on Afatinib Patients with EGFR-activating mutations in advanced lung cancer seem to benefit more fr...